Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Standard
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. / Baertsch, Marc-Andrea; Mai, Elias K; Hielscher, Thomas; Bertsch, Uta; Salwender, Hans J; Munder, Markus; Fuhrmann, Stephan; Dührsen, Ulrich; Brossart, Peter; Neben, Kai; Schlenzka, Jana; Kunz, Christina; Raab, Marc S; Hillengaß, Jens; Jauch, Anna; Seckinger, Anja; Hose, Dirk; Luntz, Steffen; Sonneveld, Pieter; Lokhorst, Henk; Martin, Hans; Goerner, Martin; Hoffmann, Martin; Lindemann, Hans-Walter; Bernhard, Helga; Blau, Igor W; Scheid, Christof; Besemer, Britta; Weisel, Katja C; Hänel, Mathias; Dürig, Jan; Goldschmidt, Hartmut; German-speaking Myeloma Multicenter Group (GMMG).
In: BLOOD CANCER J, Vol. 11, No. 1, 07.01.2021, p. 1.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
AU - Baertsch, Marc-Andrea
AU - Mai, Elias K
AU - Hielscher, Thomas
AU - Bertsch, Uta
AU - Salwender, Hans J
AU - Munder, Markus
AU - Fuhrmann, Stephan
AU - Dührsen, Ulrich
AU - Brossart, Peter
AU - Neben, Kai
AU - Schlenzka, Jana
AU - Kunz, Christina
AU - Raab, Marc S
AU - Hillengaß, Jens
AU - Jauch, Anna
AU - Seckinger, Anja
AU - Hose, Dirk
AU - Luntz, Steffen
AU - Sonneveld, Pieter
AU - Lokhorst, Henk
AU - Martin, Hans
AU - Goerner, Martin
AU - Hoffmann, Martin
AU - Lindemann, Hans-Walter
AU - Bernhard, Helga
AU - Blau, Igor W
AU - Scheid, Christof
AU - Besemer, Britta
AU - Weisel, Katja C
AU - Hänel, Mathias
AU - Dürig, Jan
AU - Goldschmidt, Hartmut
AU - German-speaking Myeloma Multicenter Group (GMMG)
PY - 2021/1/7
Y1 - 2021/1/7
N2 - Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1-21 of 28 day cycles) followed by 10-15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with
AB - Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1-21 of 28 day cycles) followed by 10-15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with
U2 - 10.1038/s41408-020-00390-3
DO - 10.1038/s41408-020-00390-3
M3 - SCORING: Journal article
C2 - 33414374
VL - 11
SP - 1
JO - BLOOD CANCER J
JF - BLOOD CANCER J
SN - 2044-5385
IS - 1
ER -
